Key Milestones
2010
Promontory Therapeutics was founded (under the name Phosplatin Therapeutics) concomitantly with its license transaction with Ohio University for a family of compounds that could be developed into anti-cancer agents.
2014
Promontory launched its First-in-Human Phase I Clinical Trial of PT-112 in Solid Tumors.
2017
PT-112 received FDA Orphan Drug Designation for use in relapsed or refractory multiple myeloma.
2018
PT-112 received FDA Orphan Drug Designation for use in thymoma and thymic carcinoma.
The PT-112-101 Phase I study team was awarded with “Best Poster” honors across the full Developmental Therapeutics category at the European Society of Medical Oncology Annual Congress in Munich, Germany.
2019
Promontory gathered industry experts during the European Society of Medical Oncology Annual Congress to review clinical data from Phase I studies of PT-112 and to explore clinical development pathways.
Promontory also presented at BIO CEO.
2020
Positive data from two phase I studies in metastatic castrate-resistant prostate cancer patients were presented at the American Society of Cancer Oncology’s Genitourinary (ASCO GU) Cancers Symposium.
Promontory also announced the publication in OncoImmunology of in vitro and in vivo data demonstrating PT-112’s bona fide induction of immunogenic cell death (ICD) and its synergistic combination with immune checkpoint inhibitors.
Promontory Therapeutics CEO Robert Fallon sat down with Proactive's Christine Corrado at the BIO CEO & Investor Conference in New York.
2022
Promontory Therapeutics received the 2022 “Cancer Immunology Solution of the Year” award in the second annual BioTech Breakthrough Awards program. The Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry.
Promontory Therapeutics CMO, Johan Baeck, MD, speaks at Sachs I-O Innovation Forum on June 2, 2023.
